Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use UPTRAVI safely and effectively. See full prescribing information for UPTRAVI. UPTRAVI® (selexipag) tablets, for oral useUPTRAVI® (selexipag) for injection, for intravenous useInitial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%) [see Clinical Studies (14.1)]. Pediatric Patients UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.
- generic_name
- selexipag
- product_names
- Selexipag
- ndc
- 66215-602, 66215-604, 66215-606, 66215-608, 66215-610, 66215-612, 66215-614, 66215-616, 66215-628, 66215-910, 66215-915, 66215-718, 66215-602-06, 66215-602-14, 66215-604-06, 66215-606-06, 66215-608-06, 66215-610-06, 66215-612-06, 66215-614-06, 66215-616-06, 66215-628-20, 66215-718-01, 66215-910-14, 66215-915-14
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en